| خلاصه مقاله | Introduction: Behcet’s disease (BD) is a chronic disease categorized among vasculitides and Interleukin (IL)-17/IL-23 pathway plays a key role in its pathogenesis. There is no exact treatment for BD and current therapeutics is established on alleviating the inflammatory status. Although reports have indicated beneficial effects of curcumin in autoimmune inflammatory diseases, there is no research evaluating the effects of curcumin in BD; therefore, this research aimed to assess the effects of curcumin supplementation on proinflammatory cytokines and disease activity in BD subjects.
Methods: In present randomized double-masked, placebo-controlled trial, 36 BD patients were randomly allocated into two groups to receive one 80 mg/day nanocurcumin capsule or placebo for 8 weeks. Before and after study, levels of proinflammatory cytokines (IL-17 and IL-23) were measured and disease activity was assessed using Behcet’s Disease Current Activity Form (BDCAF).
Results: Thirty-two patients (17 in nanocurcumin and 15 in placebo groups) completed the study. Significant reductions in IL-17 (160.41±53.6 vs. 103.59±41.41 pg/ml) and IL-23 (195.06±54.25 vs. 133.88±44.84 pg/ml) were observed in nanocurcumin group compared with baseline (P=0.017 and P=0.015) and placebo group (P=0.047 and P=0.048, respectively). Regarding disease activity, BDCAF decreased in the nanocurcumin group compared to baseline, although it did not reach to significant level: 1 (0.5, 2.0) vs. 0 (0.0, 1.0), P>0.05]. However, disease activity in the nanocurcumin group was significantly lower than placebo group at the end of trial (P=0.044).
Conclusion: Current study provided a promising view for favorable effects of nanocurcumin supplementation in ameliorating inflammatory parameters and disease activity in BD. |